
After assessing the landscape, the company is leaving the adult RSV vaccine market.
John Parkinson is the assistant managing editor for Contagion. Prior to joining MJH Life Sciences in 2020, he has covered a variety of fields and markets including diabetes, oncology, ophthalmology, IT, travel, and local news. You can email him at jparkinson@mjhlifesciences.com.

After assessing the landscape, the company is leaving the adult RSV vaccine market.

Aaron Ferguson’s diagnosis completely changed his life’s path. Since then, he has helped others overcome their addictions and get hepatitis C (HCV) treatment. In his home state of Texas, a new health initiative is looking to get more people into the continuum of care for this curable virus.

The CDC’s recent warning of the rising incidence rates of the fungal infection is cause for concern, but understanding which patients and settings are at a higher risk is equally as important. The lead author in the CDC’s recent C auris study offers some insights for both medical institutions and the general public.

The oral RNA destabilizer, AB-161, developed by Arbutus Biopharma, started dosing its first participant for the small trial.

The virus can maintain a reservoir in these white blood cells even in those who have been virally suppressed for years.

A midsized study demonstrated no therapeutic benefit to patients with mild-to-moderate COVID-19 taking this class of anthelmintics.

An intensive care physician offers some insights looking at fluoroquinolone-associated tendinopathy and using this social media platform to provide education and an open discussion around it.

Using a novel approach to identify E coli, investigators find approximately 8% of the bacterium’s isolates were foodborne zoonotic strains.

A new study reveals how US states fared, and some of the underlying reasons why the pandemic has played out in vastly different ways.

On this day of commemoration, The Bill & Melinda Gates Medical Research Institute has multiple TB therapies and a prophylactic vaccine in development, and its Chief Medical Officer Michael W. Dunne, MD, remains optimistic long-term about the state of clinical care, especially in areas of dire need such as low-and-middle-income countries.

A new study shows vaccination decreased the chances of developing the debilitating condition by nearly half.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

Climate change is causing ticks and mosquitos to migrate further north and with them comes disease, previously not seen in these geographic areas. One company is using data to model predictive vector habitats to help organizations and governments identify patterns and help prevent the spread of such diseases.

The Wistar Institute’s Amelia Escolano, PhD, is developing a novel approach using sequential immunization to capture protection against multiple strains.

It affects strawberry products that were sold at Costco and Trader Joe’s.

The incidence rate of babesiosis in Maine, Vermont, and New Hampshire saw a dramatic increase over a multiyear period and saw an increase overall in other states where the disease is endemic.

Former NBA star Magic Johnson has partnered with GSK to educate the public about this virus, specifically in seniors and those at high-risk for contracting a severe form of RSV.

The federal agency has taken a vital role in support and implementation of the ongoing PEPFAR initiative.

Bemnifosbuvir, the investigational therapy, demonstrated favorable data that was announced at this week's 2023 International Conference on Antiviral Research.

An investigator who helped draft the new recommendations discusses universal screening, the challenges of risk-based testing, and the overall goals of reducing HBV incidence rates.

In the White House’s new budget they have put aside several billion dollars towards establishing a hepatitis C (HCV) program. In addition, an HCV vaccine is expected to go into phase 1 clinical trials this year, and a pharmaceutical company is working with states to gain better therapeutic access.

One of the most significant recommendations is for all adults to be tested for the virus at least once in their lifetime.

The companies, Apotex and Pharmedica, are doing this action due to concerns of sterility of the products.

A healthcare worker and a patient with HIV concomitantly provide important clinical considerations.

The congressional bill has been on Capitol Hill for over 2 years now, and the interested stakeholders are continuing their lobbying efforts to get it passed.

The seasonal respiratory virus could be the challenging, lingering colds people are suffering with this year.

The hepatitis B vaccine (Recombinant), Adjuvanted (Heplisav-B) is approved in adults 18 years of age and older, and the vaccine’s developer, Dynavax, is working towards finding potential commercial partners for Great Britain.

A young woman who dealt with reoccurring Clostridioides difficile (CDI) in a short amount of time recounts her experience and how getting into a clinical trial made the difference in resolving her condition and getting her back to good health and her family.

The therapy, bepirovirsen, is an antisense oligonucleotide that targets all Hepatitis B (HBV) messenger RNAs, and the company is hoping it will become a functional cure.

Primary care physicians and advanced practice providers are responsible for the majority of people seeking medical care in the United States, yet there is a gap in discussing sexual health for those who are at risk of HIV or other sexually-transmitted diseases.